Le Lézard
Classified in: Health
Subjects: NPT, SVY, FDA, DIS, DEI

The Michael J. Fox Foundation Releases New Guide, "Deep Brain Stimulation and Parkinson's -- From Decision-making to Daily Life with the Device," to Answer Questions and Encourage Conversations on Available Treatments


NEW YORK, June 15, 2021 /PRNewswire/ -- As part of its mission to offer people living with Parkinson's and their families with high-quality educational resources on navigating the disease journey, The Michael J. Fox Foundation for Parkinson's Research (MJFF) today launches "Deep Brain Stimulation and Parkinson's ? From Decision-making to Daily Life with the Device." The new resource, available at michaeljfox.org/DBSguide, educates patients and care partners about deep brain stimulation (DBS) surgery as a treatment option to help manage symptoms, provides practical tips for thinking about, undergoing and living with DBS, includes perspectives and voices from the patient and family community; and shares the latest research and DBS devices available.

New Guide Developed by Parkinson's Experts Provides Answers to Questions on DBS

The new resource on DBS and Parkinson's disease (PD) was written by MJFF Senior Vice President of Medical Communications and movement disorder specialist Rachel Dolhun, MD. The guide, medically reviewed by leading Parkinson's physicians and DBS experts, was designed to include personal reflections and anecdotes from families who experienced DBS. In addition, the Foundation sourced common questions, themes, and tips on DBS through MJFF's social channels and its diverse community of people and families living with PD.

"Some of the most common questions from patients and families ? whether they've been recently diagnosed or have lived with Parkinson's for many years ? are around DBS," said Rachel Dolhun, MD. "The goal of this guide is to provide information about the DBS journey, everything from thinking about the treatment option to having the procedure and beyond. And ultimately to empower people and families to learn more, ask questions, or start conversations about this treatment option."

Patients and loved ones can use this 22-page guide to:

The free guide is available to download at michaeljfox.org/DBSguide. A webinar, featuring Parkinson's experts and community members featured within the guide, also will be available on Thursday, June 17 at 12 p.m. ET. Register for the free webinar here.

"Deep Brain Stimulation and Parkinson's ? From Decision-making to Daily Life with the Device" was made possible through support from Abbott Laboratories. Funding from our industry partners allows the Foundation to maintain editorial oversight in the creation of high-quality educational resources, while directing donor-raised dollars toward critical research.

"At Abbott, we are focused on developing life-changing deep brain stimulation technologies that seamlessly fit into a person's life and treat the symptoms of their disease," said Binith Cheeran, MD, Director of Medical Affairs for Neuromodulation, Abbott. "By partnering with The Michael J. Fox Foundation, we are able to help provide people living with Parkinson's disease and their families the educational resources they need to make informed treatment decisions to help them live their lives to the fullest." 

About Deep Brain Stimulation and the Evolution of Research

Although deep brain stimulation isn't a treatment option for everyone with PD, those who are candidates may see a substantial benefit in decreased motor symptoms and medication needs following the procedure. Today, an estimated 6 million people worldwide live with Parkinson's, a number that is expected to double by the year 2040. With an expected increase in the number of people affected by PD, resources to better understand and navigate available Parkinson's treatments are urgently needed.

Since the first DBS device was approved by the U.S. Food and Drug Administration (FDA) in 1997, it is estimated more than 160,000 DBS devices have been implanted worldwide for those living with PD, essential tremor, dystonia (muscle contractions), obsessive-compulsive disorder (OCD) and epilepsy. Patients and families typically consider DBS after being diagnosed with the disease at least four years, have trouble with how long their medications work, or have dyskinesia (involuntary movement).

Researchers are actively working to improve upon existing DBS devices and methods to help treat more symptoms and patients. Since inception in 2000, MJFF has funded more than $9 million in research into DBS for Parkinson's. Supported efforts aim to discover new brain targets for DBS and upgrade system technology to ease more symptoms, optimize outcomes and improve the user experience. Additionally, the Registry for the Advancement of Deep Brain Stimulation Therapy in Parkinson's Disease (RAD-PD) ? an MJFF-funded study ? aims to guide DBS care decisions by gathering clinician-measured and patient-reported data on the experience, methods and outcomes of DBS. RAD-PD findings could help better understand, for example, best DBS settings for symptom control, potential side effects and gaps in access to DBS therapy.

Other Foundation programs are helping build data and speed research on DBS and additional aspects of PD. MJFF's landmark Parkinson's Progression Markers Initiative study is expanding from nearly 1,400 to more than 4,000 participants ? with and without Parkinson's. Volunteers provide data through clinical exams, brain scans and contribute biological samples in pursuit of transforming how we diagnose, track, treat and potentially prevent PD. Launched in 2010, PPMI hosts an open-access data set that includes information on some volunteers with DBS. And Fox Trial Finder, MJFF's online clinical study matching tool that connects volunteers with recruiting studies in their area, lists more than 40 studies investigating DBS and Parkinson's.

"Everyone's Parkinson's journey is unique, and so are the treatment options," said Jim McNasby, JD, guide contributor and MJFF's Chief People Officer who lives with Parkinson's. "DBS provided me an opportunity to take less medication and feel a sense of independence again. My husband Donny and I welcomed the opportunity to provide our input and personal story for this guide as we know many families seek resources to better educate themselves on all aspects of the disease."

About The Michael J. Fox Foundation for Parkinson's Research

As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding $1 billion in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. 

For more information, visit us on the?Web,?Facebook,?Twitter,?LinkedIn?and?Pinterest

SOURCE The Michael J. Fox Foundation for Parkinson's Research


These press releases may also interest you

at 09:46
In the news release, NFL Alumni Performance Labs Forms Exclusive Partnership with to Deliver Best-in-Class Predictive Vital Sign Analytics, issued 20-Oct-2021 by Nervotec over PR Newswire, the release headline should read "NFL Alumni Performance Labs...

at 09:38
Skroot Laboratory, Inc. has joined the National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT). CMaT is a consortium of universities, companies, and clinical collaborators brought together to develop...

at 09:37
Encompass Health Corporation today announced that its board of directors has declared a quarterly cash dividend on its common stock of $0.28 per share, payable on Jan.18, 2022, to holders of record on Jan. 3, 2022....

at 09:30
The "Global DNA Microarray Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. The DNA microarray market is poised to grow by $2.61 bn during 2021-2025, progressing at a CAGR of 12.00%. The market is driven by advances in...

at 09:30
The global culture media market size was USD 5.43 billion in 2020 and is expected to register a CAGR of 9.3% between 2021 and 2028. Steady market revenue growth is driven by rising need for monoclonal antibodies, growing emphasis on personalized...

at 09:25
Petros Pharmaceuticals, Inc. , a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will participate in the following Benzinga events: Benzinga All Access Show Mr. Boctor will...



News published on 15 june 2021 at 08:50 and distributed by: